Decision: Favourable

Study Title:

A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis

  • NREC Code:

    22-NREC-CT-155

  • Decision:

    Favourable

  • Meeting Date:

    05/10/2022

  • Study Type:

    CT application

  • Principal Investigator:

    Prof Edward McKone

  • PI Institution:

    St Vincent's University Hospital

  • Sponsor:

    Vertex Pharmaceuticals Incorporated

Scroll to Top